Get the Stockscreener App
8.12
2.40%
-0.20
After Hours:
8.00
-0.12
-1.48%
Bicycle Therapeutics Plc Adr stock is traded at $8.12, with a volume of 192.67K.
It is down -2.40% in the last 24 hours and up +14.85% over the past month.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
See More
Previous Close:
$8.32
Open:
$8.39
24h Volume:
192.67K
Relative Volume:
0.71
Market Cap:
$404.93M
Revenue:
$36.90M
Net Income/Loss:
$-166.28M
P/E Ratio:
-2.4681
EPS:
-3.29
Net Cash Flow:
$-203.53M
1W Performance:
-1.34%
1M Performance:
+14.85%
6M Performance:
+21.19%
1Y Performance:
-69.31%
1-Day Range:
$8.00
$8.41
1-Week Range:
$7.80
$9.1592
52-Week Range:
$6.10
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Name
Bicycle Therapeutics Plc Adr
Sector
Industry
Phone
011441223261503
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
8.12 | 576.63M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Equal-Weight |
| Sep-06-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-11-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Aug-31-22 | Initiated | Cowen | Outperform |
| Jul-28-22 | Initiated | Barclays | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Apr-13-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Apr-07-22 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-14-22 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | SVB Leerink | Outperform |
| Dec-09-21 | Initiated | Needham | Buy |
| Sep-30-21 | Initiated | B. Riley Securities | Buy |
| Apr-20-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-12-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-20 | Initiated | Oppenheimer | Outperform |
| Apr-17-20 | Initiated | H.C. Wainwright | Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Sep-11-19 | Upgrade | Goldman | Neutral → Buy |
| Jun-17-19 | Initiated | Canaccord Genuity | Buy |
| Jun-17-19 | Initiated | Goldman | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
| Jun-17-19 | Initiated | Piper Jaffray | Overweight |
View All
Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 10.5%What's Next? - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 3,231 Shares - MarketBeat
Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 2,263 Shares of Stock - MarketBeat
Bicycle Therapeutics Sees Unusually Large Options Volume (NASDAQ:BCYC) - Defense World
Stock Traders Purchase High Volume of Bicycle Therapeutics Call Options (NASDAQ:BCYC) - MarketBeat
Goldman Sachs Group Inc. Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 7.8%Here's Why - MarketBeat
126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Acadian Asset Management LLC - MarketBeat
Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $22.22 - MarketBeat
126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Bought by Acadian Asset Management LLC - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
Bicycle Therapeutics appoints oncology veterans Dansey and Hoppenot to board - Investing.com India
Caption Management LLC Sells 81,517 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Armistice Capital LLC Has $22.69 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Long Focus Capital Management LLC Acquires 750,661 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR $BCYC Stock Holdings Cut by Tybourne Capital Management HK Ltd. - MarketBeat
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025 - GlobeNewswire Inc.
Candriam S.C.A. Acquires 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts’ Weekly Ratings Updates for Bicycle Therapeutics (BCYC) - Defense World
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress By Investing.com - Investing.com South Africa
Bicycle Therapeutics (NASDAQ:BCYC) Given New $13.00 Price Target at Morgan Stanley - Defense World
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - Placera.se
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
Rice Biotech Launch Pad adds TPG Life Sciences’ Carolyn Ng to board - Investing.com
Coursera (NYSE:COUR) Sees Strong Trading Volume on Analyst Upgrade - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World
Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World
Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World
Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
William Blair Brokers Decrease Earnings Estimates for TLX - Defense World
Principal Financial Group Inc. Purchases 5,315 Shares of Aaron’s Holdings Company, Inc. (NYSE:PRG) - Defense World
First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Principal Financial Group Inc. Raises Stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) - Defense World
The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX
Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa
How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com
PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com
UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com
Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com
Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN
Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com
Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bicycle Therapeutics Plc Adr Stock (BCYC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Oct 02 '25 |
Sale |
8.40 |
2,263 |
19,009 |
478,541 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Oct 03 '25 |
Sale |
8.41 |
978 |
8,225 |
118,277 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Oct 02 '25 |
Sale |
8.40 |
824 |
6,922 |
119,255 |
| Milnes Alistair | CHIEF OPERATING OFFICER |
Oct 02 '25 |
Sale |
8.40 |
1,147 |
9,635 |
94,355 |
| Milnes Alistair | CHIEF OPERATING OFFICER |
Oct 03 '25 |
Sale |
8.41 |
978 |
8,225 |
93,377 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Oct 02 '25 |
Sale |
8.40 |
473 |
3,973 |
53,352 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Oct 03 '25 |
Sale |
8.41 |
250 |
2,102 |
53,102 |
| Young Alethia | Chief Financial Officer |
Oct 02 '25 |
Sale |
8.51 |
482 |
4,103 |
44,704 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Oct 02 '25 |
Sale |
8.40 |
221 |
1,856 |
31,300 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Oct 03 '25 |
Sale |
8.41 |
103 |
866 |
31,197 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):